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Abstract
Background:  The burden of Plasmodium falciparum malaria has worsened because of the
emergence of chloroquine resistance. Antimalarial drug use and drug pressure are critical factors
contributing to the selection and spread of resistance. The present study explores the geographical,
socio-economic and behavioural factors associated with the use of antimalarial drugs in Africa.
Methods: The presence of chloroquine (CQ), pyrimethamine (PYR) and other antimalarial drugs
has been evaluated by immuno-capture and high-performance liquid chromatography in the urine
samples of 3,052 children (2–9 y), randomly drawn in 2003 from the general populations at 30 sites
in Senegal (10), Burkina-Faso (10) and Cameroon (10). Questionnaires have been administered to
the parents of sampled children and to a random sample of households in each site. The presence
of CQ in urine was analysed as dependent variable according to individual and site characteristics
using a random – effect logistic regression model to take into account the interdependency of
observations made within the same site.
Results: According to the sites, the prevalence rates of CQ and PYR ranged from 9% to 91% and
from 0% to 21%, respectively. In multivariate analysis, the presence of CQ in urine was significantly
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associated with a history of fever during the three days preceding urine sampling (OR = 1.22, p =
0.043), socio-economic level of the population of the sites (OR = 2.74, p = 0.029), age (2–5 y =
reference level; 6–9 y OR = 0.76, p = 0.002), prevalence of anti-circumsporozoite protein (CSP)
antibodies (low prevalence: reference level; intermediate level OR = 2.47, p = 0.023), proportion
of inhabitants who lived in another site one year before (OR = 2.53, p = 0.003), and duration to
reach the nearest tarmacked road (duration less than one hour = reference level, duration equal
to or more than one hour OR = 0.49, p = 0.019).
Conclusion: Antimalarial drug pressure varied considerably from one site to another. It was
significantly higher in areas with intermediate malaria transmission level and in the most accessible
sites. Thus, P. falciparum strains arriving in cross-road sites or in areas with intermediate malaria
transmission are exposed to higher drug pressure, which could favour the selection and the spread
of drug resistance.
Background
Malaria remains a major public health problem in Africa.
Around 60% of 250–500 million clinical disease episodes
and over 80% of 1.25 million deaths attributed each year
to malaria occur in sub-Saharan Africa [1]. Several studies
have described a two-fold increase in deaths due to
malaria during the 1980s and 1990s because of the emer-
gence of the chloroquine resistance [2-4]. However recent
publications have documented a decline in malaria mor-
bidity and mortality trends attributed to the increased
access to artemisinin-based combination therapies and
widespread use of insecticide-treated nets [5-7].
Drug pressure, intensity of malaria transmission and pop-
ulation movement favour the spread of antimalarial drug
resistance [8-10]. Uncontrolled antimalarial drug use is a
critical factor that contributes to the drug pressure. Explor-
ing socio-cultural factors which influence antimalarial
drug use has been recognized as a priority. Furthermore,
since one of the objectives of Roll Back Malaria was to pro-
mote an equitable coverage and access of antimalarial
drugs [11], the impact of environmental and behavioural
factors on treatment use is important to be recognized.
However, few studies have focused on this aspect of the
epidemiology of drug-resistant malaria [12,13]. The dis-
tance to public health facilities, socio-economic level, age
and parasite prevalence have been identified as key factors
of drug use, but these factors have been described gener-
ally without taking into account each other simultane-
ously. Thus, the possible associations and interactions of
these factors have never been explored. In order to evalu-
ate the association between the use of antimalarial drug
and geographical, socio-economic and behavioral factors,
a multi center cross-sectional study was conducted in
2003 in 30 sites from three countries (Senegal, Burkina
Faso and Cameroon), when CQ was still the first-line
treatment of uncomplicated malaria. Although the sites
are not formally representatives of the whole continent,
they represent a wide panel of ecosystems and malaria
endemicity conditions.
Methods
Study sites
The study was conducted in two regions (in the north and
the south of each country) in Senegal (sites #1 to 10),
Burkina-Faso (sites #11 to 20) and Cameroon (sites #21
to 30) (Figure 1), between September 30 and December
17, 2003. In each area, this period corresponded to the
end of the malaria transmission season or during the low
transmission season. The rainy season (i.e. with an aver-
age of five or more rainy days per month in the nearest
locality referred at http://www.meteofrance.com/FR/cli
mat/clim_afriq.jsp#) lasts from August to September,
from June to October, from May to September, from May
to October and from May to October, in north Senegal,
south Senegal, north Burkina-Faso, south Burkina-Faso
and north Cameroon, respectively. In south Cameroon,
there are two rainy seasons from March to June and from
September to November. A list of different possible com-
binations of five sites (districts of towns or villages) was
established for each region. The combinations were made
to maximize the differences in environmental conditions
suitable for malaria transmission, access to health struc-
tures and transport facilities between sites. A combination
of five sites was randomly selected from the list of each
region. In Burkina Faso, the combination of sites included
three sites in an urban area and two sites in a rural area. In
the regions of the other countries, only rural sites were
included.
The informed consent of the parents of each child was
obtained orally at the beginning of the study after a thor-
ough explanation of its purpose. The study design
received clearance from the Senegal (Dakar), Burkina Faso
(Ouagadougou) and Cameroon (Yaoundé) National Eth-
ics Committees.
Site characteristics
In each site, 30 households were randomly selected from
a numbered households list when it was available for the
site or using a random-walk that was calibrated to be ableMalaria Journal 2008, 7:124 http://www.malariajournal.com/content/7/1/124
Page 3 of 12
(page number not for citation purposes)
to cover the whole of the surface of the site and started
from its center.
The head of each household was interviewed on the
number of individuals in the household, the number of
rooms occupied, and the presence of the following facili-
ties: running water, electricity, kitchen, refrigerator, living
room, dining room, television, radio, video recorder,
mobile, landline phone, vehicle, characteristics of the
house (wall without anfractuosities, ground built with
tiles or cement, windows that can be closed hermetically,
roof built with a permanent structure). The number of
these facilities that were present was calculated and used
as an unweighted score from 0 to 16 reflecting the socio-
economic level of each household.
A numbered list of all the inhabitants was drawn up for
each household. Among them, up to three individuals
were randomly chosen using a random numbers table.
These individuals or their legal tutor were interviewed on
their history of previous malaria attack, their personal
characteristics (including age, last travel outside his/her
village or town, length of residence in the site), their trav-
els (number of nights spent in another village in the last
30 days) and their use of antimalarial drugs (including
names of anti-malarial drugs commonly used, places
where drugs are purchased, presence of stocks of medi-
cines in the household). The sites were characterized by
aggregating data collected from individuals or households
(by calculating the median or proportion). Distances
between sites and towns, sanitary structures and transport
Map of the study areas in West and Central Africa Figure 1
Map of the study areas in West and Central Africa. Study sites are indicated by open discs and their ID numbers on the maps 
of the study areas. Hydrographic networks are in white. Road networks are in black. Main localities are indicated by filled discs.Malaria Journal 2008, 7:124 http://www.malariajournal.com/content/7/1/124
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system were obtained from global positioning system
coordinates. The duration of the corresponding travel
were estimated by the averaged responses from key per-
sons and heads of households.
People
The consumption of antimalarial drug was estimated by
testing the presence of chloroquine (CQ) and pyrimeth-
amine (Pyr) parent compounds and metabolites in urine
samples of 100 children between two and nine years of
age randomly selected in each site, independently of their
clinical status. Parental consent was obtained for each
child. The test is based on an enzyme-linked immuno-
sorbent assay (ELISA) blocking test, where immobilized
antibody was first reacted with the test sample and then
with a drug-peroxidase-enzyme conjugate and finally with
the peroxidase-enzyme-substrate [14]. The sensitivity for
the detection of CQ and Pyr were 20 ng/ml and 50 ng/ml,
respectively. The specificity in negative controls was
100%. The presence of antimalarials in urine was also
tested in a random sub-sample of urine from each country
using an high-performance liquid chromatography
(HPLC) technique. A numbered list of all the urines was
drawn up for each country. Among them, up to hundred
urine samples were randomly chosen using computer-
generated random numbers and sent at -20°C to France
and then kept at -80°C until analysis. Samples without
sufficient volume of urines (e.g. that were spilt during the
transport) were not processed. HPLC allows the detection
of CQ (the sensitivity has been defined for each mole-
cule), amodiaquine, quinine, mefloquine, halofantrine,
proguanil, sulphadoxine, doxycycline and pyrimeth-
amine, as described elsewhere [15,16].
Fingerprick capillary blood was obtained to prepare
Giemsa-stained thick smears. Parasite density and the
number of trophozoites against 100 leukocytes were cal-
culated for each Plasmodium species. Blood spots were
collected and dried on Whatman® 3 MM filter paper. IgG
antibody against P. falciparum circumsporozoite protein
(CSP) was measured in dried blood samples using elution
and ELISA techniques described elsewhere [17,18]. Sites
were classified according the prevalence of anti-CSP anti-
bodies: low (less than 20%), intermediate (20 – < 40%)
and high (≥ 40%).
For each child, information on site, age, sex, clinical status
(fever during the last three days), consumption of anti-
malarial drugs during the last seven days, travel during the
last month was collected by questionnaires.
Statistical methods
Data were entered using EpiDATA v3.0 [19] and checked
for consistency before statistical analysis using R 2.5.0.
Descriptive analysis was done to determine the level of
use of CQ and PYR, of anti-CSP antibodies, malaria or
parasite rate and other characteristics by site.
The presence of CQ in urine was analysed as a dependent
variable according to individual and site characteristics
using a random-effect logistic regression model to take
into account the interdependency of observations made
within the same site.
A bivariate analysis was first performed by entering each
independent variable in the logistic model. Variables were
retained for the multivariate analysis when their effects
had a p-value lower than 0.25. A multivariate analysis was
done in two steps. First, an empty regression model was
developed to evaluate the between-sites random varia-
tion. This was followed by the selection of children and
site characteristics in the bivariate analysis and added to
the model. Then a multivariate analysis was performed by
a backward step-by-step procedure. The independent var-
iables and their interactions were retained in the model if
their effects were significant (likelihood ratio statistic, p <
0.05). The adequacy of the final model was estimated by
the area under the receiver operating characteristic (ROC)
curve and by looking at the adequacy between observed
and predicted probabilities of detecting CQ in children's
urine samples in each site.
Results
Site description
In the 30 sites, 3,231 children between two and nine years
of age and 3,097 individuals from 1,109 households were
randomly selected (Table 1). The prevalence of P. falci-
parum trophozoites was significantly (p < 0.05) different
between sites. It varied from 16.2% (site 2) to 96.1% (site
18) (Table 2), with a median of 72%. It was significantly
higher in the south than in the north of Senegal (72% ver-
sus 25%, p < 10-3), Burkina Faso (79% versus 64%, p < 10-
3), and Cameroon (78% versus 61%, p < 10-3), and also
higher in rural than in urban areas of Burkina Faso (84%
versus 64%, p < 10-3). It was higher among children older
than five years than among children below five years of
age (65% versus 59%, p = 0.002).
The prevalence of anti-CSP-antibodies varied from 9.5%
(sites 2 and 4) to 96.1% (site 12) (Table 2) according to
sites, with a median of 31%. It was significantly higher in
the south than in the north in Senegal (54% versus 14%,
p < 10-3) and in Burkina Faso (70% versus 49%, p < 10-3).
In Cameroon, it was lower in the south (25% versus 32%
p < 10-3). It was significantly higher in rural than in urban
areas of Burkina Faso (86% versus 44%, p < 10-3) and
higher among children aged more than five years old than
among children aged less than five years (48% versus
32%, p < 10-3).Malaria Journal 2008, 7:124 http://www.malariajournal.com/content/7/1/124
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The time necessary to join the nearest tarmacked road var-
ied from 0 to 8.5 hours with a median of one hour. The
proportion of inhabitants who lived in another site one
year before the survey varied from 0% to 25% with a
median of 4.3%. The average index of the household
socio-economic level varied from 0.9 to 8.7 with a median
of 3. No systematic distribution of antimalarial drugs to
the children had been organized in the sites during six
previous months. The others sites characteristics (i.e. indi-
vidual or household data aggregated by site) are presented
in Additional Files 1 and 2.
Chloroquine in urine
CQ was tested in urine samples by dipstick in 3,052 of
3,231 children, aged 2–9 years (no urine was available for
179 children, i.e. 5% of the randomized children). Males
represented 49.9% of the children for whom urine sam-
ples were available. The characteristics of the other chil-
dren are detailed in Additional File 3. Among these 3,052
children, 41.4% had CQ in their urine (1262/3052). The
prevalence of CQ in children urine samples varied from
9.0% (site 7) to 90.1% (site 13) with a median of 32.2%.
The prevalence of CQ in urine was significantly different
between countries (Senegal = 22%, Burkina Faso = 47%
and Cameroon = 55%, p < 10-3), between regions within
the same country (i.e.  higher in the north than in the
south in Senegal [29% versus 14%, p < 10-3 ], in Burkina
Faso, [63% versus 31%, p < 10-3 ], and in Cameroon,
[66% versus 44%, p < 10-3 ]) and between sites from the
same region (Table 2). It was significantly higher in urban
than in rural areas of Burkina Faso (59% versus 37%, p =
0.047).
The prevalence of CQ in urine samples was higher in sites
with a moderate prevalence rate of anti-CSP antibodies
(61%) than in sites with a low (39%, p <0.026) or high
prevalence rate of anti-CSP antibodies (23%, p = 0.088).
The prevalence of CQ in children's urine was higher in
those aged ≤ 5 years old than in children aged > 5 years
old (49% versus 35%, p = 0.001). This difference was
observed independently of the prevalence of anti-CSP
antibodies in the sites (Figure 2).
The prevalence of CQ in urine was higher in children with
a history of fever during the three days before urine sam-
Table 1: Study sites. ID number, country, region, type of area and geographical coordinates.
Site's name ID Country Region type of 
area
Latitude
degree
Longitude 
degree
THIAGO 1 Senegal North rural 16.4 -15.72
TEMEYE SALANE 2 Senegal North rural 16.33 -15.77
SANINTE 3 Senegal North rural 16.23 -15.8
NDIAKHAYE 4 Senegal North rural 16.18 -15.82
MALLA 5 Senegal North rural 16.12 -15.87
TIABEDJI 6 Senegal South rural 12.63 -12.4
SAMAL 7 Senegal South rural 12.67 -12.5
THIOBO BANTATA 8 Senegal South rural 12.67 -12.33
ASSONI 9 Senegal South rural 12.65 -12.49
LANDE RUNDE. LANDE BAITIL 10 Senegal South rural 12.55 -12.40
TIPTENGA 11 Burkina Faso North rural 13.09 -0.81
FATIN 12 Burkina Faso North rural 12.93 -0.95
OUAGADOUGOU S29–30 13 Burkina Faso North urban 12.35 -1.47
OUAGADOUGOU PISSY S17 14 Burkina Faso North urban 12.34 -1.56
OUAGADOUGOU NIOKO II S26 15 Burkina Faso North urban 12.42 -1.47
NIENA 16 Burkina Faso South rural 11.72 -4.72
TENASSO 17 Burkina Faso South rural 11.28 -4.93
BOBO-DIOULASSO SAMAGAN 18 Burkina Faso South urban 11.13 -4.35
BOBO-DIOULASSO DOGONA 19 Burkina Faso South urban 11.2 -4.28
BOBO-DIOULASSO KUINIMA 20 Burkina Faso South urban 11.15 -4.28
YOUKOUT 21 Cameroon North rural 8.29 14.09
TCHOLLIRE II 22 Cameroon North rural 8.45 14.26
SAKDJE 23 Cameroon North rural 8.27 13.65
BOCKI 24 Cameroon North rural 8.75 13.53
KATE 25 Cameroon North rural 8.78 13.52
MELEN/NKOLAFENDEK 26 Cameroon South rural 2.77 12.52
MIATTA/DJOUZE 27 Cameroon South rural 2.73 12.63
ENDEGUE/ABDELON 28 Cameroon South rural 2.69 12.64
ZOEBEFAM/NKOLEMBOULA 29 Cameroon South rural 2.72 13.34
YEN/MEBAN II 30 Cameroon South rural 2.43 12.67Malaria Journal 2008, 7:124 http://www.malariajournal.com/content/7/1/124
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Table 2: Prevalence of Plasmodium falciparum trophozoites, anti-CSP antibodies and antimalarial drugs detected in children between 
two and nine years of age.
ID Site Nb of thick 
smears
Prevalence of 
trophozoites 
(all species)
Prevalence of 
Plasmodium 
falciparum 
trophozoites
Prevalence of anti-CSP 
antibodies
Detection of antimalarial drugs in 
children's urines
Nb of thick 
smears +
(%)
Nb of thick
smears +
(%)
Nb of 
serology
Nb of 
serology +
(%)
CQ* PYR†
CQ+‡ Prevalence 
(95% CI)
PYR+§ Prevalence 
(95% CI)
1 100 26 (26.0) 25 (25.0) 100 13 (13.0) 36 36.0 
(26.6–46.2)
0 0.0 
(0.0–3.6)
2 105 17 (16.2) 17 (16.2) 105 10 (9.5) 18 18.0 
(11.0–26.9)
0 0.0 
(0.0–3.6)
3 111 21 (18.9) 19 (17.1) 110 13 (11.8) 16 14.5 
(8.5–22.5)
0 0.0 
(0.0–3.3)
4 120 23 (19.2) 22 (18.3) 118 12 (10.2) 56 47.5 
(38.2–56.9)
0 0.0 
(0.0–3.1)
5 101 54 (53.5) 47 (46.5) 100 25 (25.0) 26 25.7 
(17.6–35.4)
2 2.0 
(0.2–7.0)
6 100 79 (79.0) 72 (72.0) 100 55 (55.0) 20 20.0 
(12.7–29.2)
0 0.0 
(0.0–3.6)
7 100 86 (86.0) 79 (79.0) 100 48 (48.0) 9 9.0 
(4.2–16.4)
0 0.0 
(0.0–3.6)
8 103 89 (86.4) 83 (80.6) 103 75 (72.8) 14 14.0 
(7.9–22.4)
0 0.0 
(0.0–3.6)
9 84 60 (71.4) 57 (67.9) 84 39 (46.4) 18 21.4 
(13.2–31.7)
0 0.0 
(0.0–4.3)
10 110 78 (70.9) 66 (60.0) 110 51 (46.4) 10 9.1 
(4.4–16.1)
0 0.0 
(0.0–3.3)
11 102 90 (88.2) 90 (88.2) 104 93 (89.4) 47 46.1 
(36.2–56.2)
1 1.0 
(0.0–5.3)
12 102 93 (91.2) 88 (86.3) 102 98 (96.1) 33 33.7 
(24.4–43.9)
0 0.0 
(0.0–3.7)
13 102 41 (40.2) 41 (40.2) 104 21 (20.2) 98 90.7 
(83.6–95.5)
1 0.9 
(0.0–5.1)
14 102 42 (41.2) 38 (37.3) 105 22 (21.0) 89 80.2
(71.5–87.1)
0 0.0 
(0.0–3.3)
15 100 69 (69.0) 68 (68.0) 101 24 (23.8) 60 61.9 
(51.4–71.5)
0 0.0 
(0.0–3.7)
16 117 100 (85.5) 99 (84.6) 115 82 (71.3) 18 16.7 
(10.2–25.1)
0 0.0 
(0.0–3.4)
17 102 79 (77.5) 78 (76.5) 102 88 (86.3) 18 20.0 
(12.3–29.8)
1 1.1 
(0.0–6.0)
18 102 98 (96.1) 98 (96.1) 105 93 (88.6) 18 18.4 
(11.3–27.5)
0 0.0 
(0.0–3.7)
19 101 88 (87.1) 88 (87.1) 104 78 (75.0) 31 31.3 
(22.4–41.4)
0 0.0 
(0.0–3.7)
20 104 55 (52.9) 53 (51.0) 104 30 (28.8) 66 68.8 
(58.5–77.8)
1 1.0 
(0.0–5.7)
21 101 65 (64.4) 55 (54.5) 99 23 (23.2) 49 51.0 
(40.6–61.4)
20 20.8 
(13.2–30.3)
22 103 83 (80.6) 80 (77.7) 66 25 (37.9) 89 89.0 
(81.2–94.4)
0 0.0 
(0.0–3.6)
23 101 79 (78.2) 72 (71.3 99 46 (46.5) 35 34.7 
(25.5–44.8)
1 1.0 
(0.0–5.4)
24 101 65 (64.4) 59 (58.4) 99 32 (32.3) 68 67.3 
(57.3–76.3)
0 0.0 
(0.0–3.6)
25 100 52 (52.0) 41 (41.0) 86 16 (18.6) 91 87.5 
(79.6–93.2)
0 0.0 
(0.0–3.5)Malaria Journal 2008, 7:124 http://www.malariajournal.com/content/7/1/124
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pling than in children with no history of fever (51% ver-
sus 38%, p = 0.032), and in children who had traveled out
of the site during the month before urine sampling than
children who did not leave the site (48% versus 41%, p =
0.048).
The prevalence of CQ in urine was higher in sites with
more than 5% of inhabitants living in another site one
year before urine sampling (49% versus 33%, p = 0.058),
in sites with an average socio-economic level equal to 6 or
higher (68% versus 36%, p = 0.002) and in sites in which
the duration to join the nearest tarmacked road was less
than one hour (48% versus 36%, p = 0.206). The other
results of the bivariate analysis are presented in Tables 3
and 4 and in Additional File 4.
There was no significant interaction between variables
retained in the model. In multivariate analysis, the preva-
lence of CQ in urine was lower among children above five
years of age (OR = 0.76, 95% CI = 0.64–0.90), and in sites
in which the duration to join the nearest tarmacked road
was one hour or more (OR = 0.49, 95% CI = 0.27–0.89).
It was higher among children who declared a febrile epi-
sode during the three days preceding the urine sampling
(OR = 1.22, 95% CI = 1.01–1.49), in sites with a high
average socio-economical level (OR = 2.74, 95% CI =
1.11–6.78), in sites with more than 5% of inhabitants liv-
ing in another site one year before urine sampling (OR =
2.53, 95% CI = 1.11–6.78) and in sites with a prevalence
rate of anti-CSP antibodies among two to nine-year old
children comprised between 20 and 39.9% (OR = 2.47,
95% CI = 1.13–5.41) (Table 5). The area under the ROC
curve was 0.764. Additional File 5 shows the adequacy
between observed and expected prevalence of CQ in urine
according to the final model.
Pyrimethamine in urine
PYR was tested using the same dipstick as CQ. The preva-
lence of PYR in children's urine samples varied from 0%
to 21% (site 21) with a median of 0%. It was 0.2%, 0.4%
and 2.2% in Senegal, Burkina Faso and Cameroon, respec-
tively. Because of the low prevalence rate of PYR in urine,
no bivariate or multivariate analysis was done.
Detection of antimalarials in urines using HPLC
HPLC measurement of CQ was performed for 280 urine
samples (i.e.  93, 98 and 89 children from Senegal,
Burkina Faso and Cameroon, respectively). The preva-
lence of CQ detected by HPLC was 27%, 45% and 51% in
Senegal, Burkina Faso and Cameroon, respectively. These
prevalence rates were not significantly different from
those estimated using dipsticks.
The prevalence of PYR detected by HPLC was 0%, 2% and
3% in Senegal, Burkina Faso and Cameroon, respectively.
Amodiaquine was detected by HPLC in 6% (16/280) of
the urine samples. Its prevalence rate was 2%, 8% and 7%
in Senegal, Burkina Faso and Cameroon, respectively.
Quinine was detected by HPLC in 1% (3/280) of the
urines. Its prevalence rate was 0%, 1% and 2% in Senegal,
Burkina Faso and Cameroon, respectively. Mefloquine,
26 101 86 (85.1) 74 (73.3) 102 29 (28.4) 56 55.4 
(45.2–65.3)
0 0.0 
(0.0–3.6)
27 99 83 (83.8) 81 (81.8) 48 8 (16.7) 28 27.2 
(18.9–36.8)
0 0.0 
(0.0–3.5)
28 104 87 (83.7) 84 (80.8) 95 21 (22.1) 42 39.6 
(30.3–49.6)
0 0.0 
(0.0–3.4)
29 103 81 (78.6) 76 (73.8) 103 22 (21.4) 25 24.3 
(16.4–33.7)
0 0.0 
(0.0–3.5)
30 107 91 (85.0) 86 (80.4) 107 34 (31.8) 78 72.9 
(63.4–81.0)
2 1.9 
(0.2–6.6)
Total 3088 2060 (66.7) 1936 (62.7) 2980 1226 (41.1) 1262 41.3 
(39.6–43.0)
29 1 (0.6–1.4)
Nb: number; %, percent, *CQ: Chloroquine, † PYR: Pyrimethamine, ‡ CQ+ = number of samples with chloroquine in urine, §PYR+: number of 
samples with pyrimethamine in urine, Prevalence: expressed in percent.
Table 2: Prevalence of Plasmodium falciparum trophozoites, anti-CSP antibodies and antimalarial drugs detected in children between 
two and nine years of age. (Continued)
Prevalence rate (and 95% confidence interval) of chloroquine  in urines of children between two and nine years of age  according to their age and the prevalence rate of anti-CSP  antibody among the children of the sites Figure 2
Prevalence rate (and 95% confidence interval) of chloroquine 
in urines of children between two and nine years of age 
according to their age and the prevalence rate of anti-CSP 
antibody among the children of the sites. *CQ: chloroquine.Malaria Journal 2008, 7:124 http://www.malariajournal.com/content/7/1/124
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halofantrine, proguanil, sulphadoxine and doxycycline
were not detected in any of the samples.
Discussion
CQ was the first-line antimalarial drug used in 2003 in
Senegal, Burkina Faso and Cameroon among children
between two and nine years of age. Other studies had
shown that CQ was the main antimalarial drug used in
Africa [20-22]. For example, in the study of Talusina et al
conducted in 1998 and 1999 in Uganda, the prevalence of
CQ in urine obtained from children between one and
nine years of age was 48% [10]. According to the sites, CQ
was present in 9% to 90% (median 32%) of the urine
samples collected in the present study. One of the signifi-
cant findings of the study was the wide range of CQ prev-
alence observed from one site to another, including
within the same region. Six factors associated with the het-
erogeneity of antimalarial drug use were identified.
History of fever, age and socio-economic level
Three of these factors were expected. The first expected fac-
tor was the history of fever in days preceeding urine sam-
pling. In case of fever, parents usually administer
antimalarial drugs to their children as a presumptive treat-
ment [22-24]. Second, the prevalence of CQ in urine was
lower among children older than five years, most of
whom have acquired antimalarial immunity during the
first five years of permanent residence in an endemic area
[25,26]. This association between age and CQ consump-
tion was observed independently of the anti-CSP antibod-
ies prevalence rate, i.e. the level of malaria transmission.
The third expected factor was the average socio-economic
level. High socio-economic level is associated with the
ability to seek health service. In the study by Biritwun et al
[27], conducted in Ghana, children from poorer commu-
nity were less likely to take antimalarial treatment in a
clinic or hospital as compared with children from a better-
off community. These three factors are similar to those
identified in earlier studies on the treatment given for
fever [28,29].
Population mobility
Three less expected factors associated with CQ consump-
tion have been identified in the present study. First, the
prevalence of CQ in children's urine was higher in sites
where the proportion of inhabitants living in another site
one year ago was higher. Thus, drug pressure was highest
in sites where population migration was most frequent.
Second, the prevalence of CQ intake was higher in sites
where the duration to join the nearest tarmacked road was
shorter. Thus, drug pressure was highest in most accessible
sites. It is possible that accessibility by tarmacked road
facilitates access to health services, independently of the
socio-economic level. These two factors indicate that pop-
ulation mobility in relation to migration and site accessi-
bility is positively associated with a more frequent
antimalarial drug use. Two consequences may be
expected: i) probability of resistant P. falciparum strain
imported from another region or country is higher, ii)
selective drug pressure on the Plasmodium population is
higher. It could have facilitated the diffusion of chloro-
quino-resistance [8,30]. It is the first time that antimalar-
ial drug use is shown to be associated with population
mobility.
Malaria transmission
The last factor associated with the presence of CQ in chil-
dren's urine was the level of anti-CSP antibodies. The
Table 3: Chloroquine prevalence in urines of children between two and nine years of age according to children characteristics. 
Variables N* CQ+† Prevalence of
presence of CQ‡ %
crude OR 95%CI p
Sex Male 1524 618 41 1.00
Female 1528 644 42 1.07 0.90 1.26 0.458
Age 2–5 years old 1419 691 49 1.00
6–9 years old 1633 571 35 0.74 0.63 0.89 0.001
Fever during the preceeding 3 days without 2252 852 38 1.00
with 800 410 51 1.24 1.02 1.50 0.032
Antimalarial treatment during the preceding 7
days
no 2652 995 38 1.00
yes 400 267 67 1.90 1.46 2.47 0.000
Travel during the preceding 30 days no 2930 1203 41 1.00
yes 122 59 48 1.52 1.00 2.30 0.048
Malaria infection no 974 466 48 1.00
yes 1939 718 37 0.60 0.49 0.74 0.000
Asexual Plasmodium falciparum infections no 1094 518 47 1.00
yes 1819 666 37 0.61 0.50 0.75 0.000
*N number of samples of urine, † CQ+ = number of samples with chloroquine in urines, ‡ CQ: Chloroquine.
Logistic regression model with random effect taking into account the interdependency of observations made within the same site.Malaria Journal 2008, 7:124 http://www.malariajournal.com/content/7/1/124
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prevalence of anti-CSP antibodies was used as a proxy of
the level of intensity of malaria transmission. This level is
usually measured by determining the entomological inoc-
ulation rate. Parasite prevalence can be used as an alterna-
tive proxy [31], but in the present study the prevalence of
anti-CSP antibodies was preferred because it is not modi-
fied by antimalarial treatment [32] or parasite resistance
to drugs. CSP is actively expressed only during the sporo-
zoite stage and is generally used as a proxy of the level of
exposure to malaria [33]. In the present study, the preva-
lence of CQ in children's urine was higher in sites where
the prevalence of anti-CSP antibodies was intermediate
(between 20 and 39.9%). There are contrasting views on
the role of transmission intensity of P. falciparum on drug
consumption and spread of CQ resistance. In the study by
Talisuna et al, conducted in seven sites in Uganda and
involving 1,504 people aged 1–45 years, CQ use in all
ages was inversely related to parasite prevalence [10]. The
Table 4: Chloroquine prevalence in urines of children between two and nine years of age according to site's characteristics. 
Site's characteristics N* CQ+† Prevalence of CQ‡ % crudeOR 95%CI p
Country Senegal 1023 223 22 1.00
Burkina Faso 1007 478 47 3.69 1.49 9.16 0.005
Cameroon 1022 561 55 5.54 2.23 13.72 0.000
Region North 1547 811 52 1.00
South 1505 451 30 0.31 0.15 0.66 0.002
Type of area rural 2443 900 37 1.00
urban 609 362 59 2.93 1.01 8.46 0.047
Prop. ‡ living in an other locality one year before the
study
< 5% 1424 471 33 1.00
>= 5% 1628 791 49 2.29 0.97 5.40 0.058
Prop. ‡ living in an other site for more than 1 month
during the preceding year
< 15% 1920 685 36 1.00
>= 15% 1132 577 51 2.24 0.92 5.45 0.077
Proportion of visitors among individuals present in
the households the night before
< 2% 1918 635 33 1.00
>= 2% 1134 627 55 3.02 1.29 7.07 0.011
Prop. ‡ had a not damaged bed-net < 30% 1826 868 48 1.00
>= 30% 1226 394 32 0.48 0.20 1.15 0.100
Prop. ‡ had access to stockpiles of antimalarial drugs
at home
< 20% 1955 605 31 1.00
>= 20% 1097 657 60 4.05 1.86 8.81 0.000
Average number of individuals by household < 7 834 501 60 1.00
7–9 1293 504 39 0.35 0.13 0.93 0.035
>= 10 925 257 28 0.21 0.07 0.61 0.004
Socioeconomic level score in 2 classes <6 2540 914 36 1.00
>= 6 512 349 68 4.73 1.74 12.87 0.002
Length of the travel to join the nearest sanitary
structure
< 1 km 404 304 75 1.00
1–9.9 km 1034 425 41 0.20 0.06 0.67 0.010
>= 10 km 1614 533 33 0.13 0.04 0.42 0.001
Length of the travel to join the pharmacy the most
used
< 5 km 504 340 67 1.00
5–9.9 km 1034 425 41 0.29 0.09 0.95 0.041
>= 10 km 1514 497 33 0.19 0.06 0.57 0.003
Duration of the route to join the nearest tarmacked
road
< 1 hour 1336 640 48 1.00
>= 1 hour 1716 622 36 0.56 0.23 1.37 0.206
Prevalence rate of the anti-CSP antibodies among
children between two and nine years of age
< 20% 635 245 39 1.00
20–39.9% 1227 746 61 2.81 1.13 6.97 0.026
>= 40% 1190 271 23 0.44 0.17 1.12 0.088
Prevalence rate of P. falciparum trophozoites among
children between two and nine years of age
< 25% 428 126 29 1.00
25–49% 526 351 67 6.62 1.67 26.23 0.007
50–74% 989 407 41 1.76 0.52 5.92 0.359
>= 75% 1109 378 34 1.27 0.38 4.21 0.693
*N number of samples of urine, † CQ+ = number of samples with chloroquine in urines, ‡ Prop.: proportion of inhabitants of the site who
Logistic regression model with random effect taking into account the interdependency of observations made within the same site.Malaria Journal 2008, 7:124 http://www.malariajournal.com/content/7/1/124
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authors attributed this association with parasite preva-
lence, i.e. malaria endemicity, to the more rapid acquisi-
tion of antimalarial immunity in areas where the exposure
to malaria infection is higher. A limitation of this study
was the use of the parasite prevalence as the indicator for
transmission intensity: this variable could be biased by
drug use and drug resistance. In the present study, inter-
mediate prevalence rate of anti-CSP antibodies, i.e. inter-
mediate level of transmission, was significantly associated
with higher consumption of CQ. It is consistent with the
observation of Trape and Rogier who have reported that
the cumulated incidence of clinical malaria was higher in
intermediate endemic areas [4].
In terms of the spread of CQ resistance, there are three
conflicting hypotheses on the role of malaria transmission
[8,9]. The first hypothesis suggests that low transmission
level increases the rate of spread of resistance because
resistance gene combinations would be more stable and
hence spread faster [34,35]. The second suggests that
resistant parasites spread faster when transmission is high
if intra-host dynamics exist: the increasing transmission
intensity can increase the number of co-infecting clones,
and antimalarial drug use would eradicate the drug sus-
ceptible clones and allow the survival of the resistant
clones [35]. The third hypothesis suggests that the inten-
sity of transmission intensity plays no role in the early
stages of the evolution of parasite resistance [36]. All of
these hypotheses do not take into consideration the effect
of drug use. The present study shows that drug selection
pressure was different between sites with different levels
of transmission intensity. This observation should be
taken into account for modeling the spread of drug resist-
ance in relation to malaria transmission and acquisition
of clinical immunity.
Diversity of antimalarial drug use
Few drugs other than CQ were present in the urine sam-
ples analysed in the present study. The prevalence of
pyrimethamine in urine ranged from 0 to 21% (median
0%), depending on the sites. This could at least partly
explain the low level of antifolate resistance during the
study. In the meta-analysis of Talusina et al, the median of
the prevalence of sulphadoxine-pyrimethamine (SP)
Table 5: Multivariate analysis of the presence of chloroquine in urines of children between two and nine years of age. 
Variables N CQ+* Prevalence of CQ † % Crude OR 95%CI p‡ Adjusted OR 95%CI p‡
Age
2–5 years old 1419 691 49 1.00 1.00
6–9 years old 1633 571 35 0.74 0.09 0.63 0.001 0.76 0.64 0.90 0.002
Fever during the preceding 
3 days
without 2252 852 38 1.00 1.00
with 800 410 51 1.24 1.02 1.50 0.032 1.22 1.01 1.49 0.043
Proportion of individuals 
who were living in an other 
locality one year before 
the study
< 5% 1424 471 33 1.00 1.00
>= 5% 1628 791 49 2.29 0.97 5.40 0.058 2.53 1.38 4.64 0.003
Score in 2 classes 
representing the 
households' average 
socioeconomic level
< 6 2540 914 36 1.00 1.00
>= 6 512 349 68 4.73 1.74 12.87 0.002 2.74 1.11 6.78 0.029
Prevalence rate of the anti-
CSP antibodies
< 20% 635 245 39 1.00 1.00
20–39.9% 1227 746 61 2.82 1.11 7.16 0.0289 2.47 1.13 5.41 0.023
>= 40% 1190 271 23 0.44 0.17 1.12 0.0885 0.68 0.32 1.43 0.305
Duration of the route to 
join the nearest tarmacked 
road
< 1 hour 1336 640 48 1.00 1.00
>= 1 hour 1716 622 36 0.56 0.23 1.37 0.206 0.49 0.27 0.89 0.019
*CQ+ = number of samples with chloroquine in urines, † CQ: Chloroquine, ‡ p: p-value
Logistic regression model with random effect taking into account the interdependency of observations made within the same site.Malaria Journal 2008, 7:124 http://www.malariajournal.com/content/7/1/124
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treatment failure in Africa between 1996 and 2002 varied
from 0 to 35% [8]. The widespread adoption of intermit-
tent preventive treatment using SP in pregnant women
could lead to an increased prevalence of resistances to this
drug in the next future. Since 2001 the World Health
Organization recommends that treatment policies in all
countries experiencing resistance of P. falciparum to con-
ventional monotherapies should be combination thera-
pies, preferably those containing artemisinin derivatives
[37]. However, a change in national antimalarial treat-
ment policies can take several years. In 2003, CQ was still
the usual treatment in the three countries where the
present study was conducted.
Evaluating drug consumption
To assess the level of antimalarial drug consumption, two
methods can be used: questionnaires and biological
methods for detecting drugs in urine or blood. The assess-
ment of antimalarial drug consumption by question-
naires is less reliable than biological methods because of
misunderstanding of questions, failed memory, or delib-
erate attemps to provide false information [10,13,20]. In
the present study, drug consumption was assessed by a
CQ- and PYR-specific dipstick. The urine dipstick detects
the presence of CQ and PYR and, by cross-reaction, also
detects amodiaquine and proguanil. However, the stand-
ard method to detect and measure antimalarial drugs in
urine and blood is high-performance liquid chromatogra-
phy (HPLC). Since the latter is more expensive than urine
dipstick, it was not used for all samples in this study. Pro-
guanil was not found in urine by HPLC, and amodiaquine
was present in only 6% of the samples. Therefore, the
analysis of antimalarial consumption seems not biased by
cross reactions.
Conclusion
Antimalarial drug pressure considerably varied from one
site to another, including within the same region, and was
significantly higher in areas with intermediate malaria
transmission level, i.e. where the level of acquired malaria
immunity is intermediate, and in the most accessible sites.
Therefore, incoming resistant P falciparum strains from
other sites would find favourable conditions to become
established and spread in the receiving human popula-
tion.
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